Growth Metrics

Novavax (NVAX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$4.6 billion.

  • Novavax's Retained Earnings rose 693.56% to -$4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.6 billion, marking a year-over-year increase of 693.56%. This contributed to the annual value of -$5.0 billion for FY2024, which is 388.93% down from last year.
  • Per Novavax's latest filing, its Retained Earnings stood at -$4.6 billion for Q3 2025, which was up 693.56% from -$4.4 billion recorded in Q2 2025.
  • Novavax's Retained Earnings' 5-year high stood at -$2.1 billion during Q1 2021, with a 5-year trough of -$5.0 billion in Q4 2024.
  • Its 5-year average for Retained Earnings is -$4.1 billion, with a median of -$4.5 billion in 2025.
  • Per our database at Business Quant, Novavax's Retained Earnings crashed by 9303.98% in 2021 and then surged by 963.46% in 2025.
  • Over the past 5 years, Novavax's Retained Earnings (Quarter) stood at -$3.6 billion in 2021, then decreased by 18.19% to -$4.3 billion in 2022, then fell by 12.75% to -$4.8 billion in 2023, then fell by 3.89% to -$5.0 billion in 2024, then increased by 8.44% to -$4.6 billion in 2025.
  • Its Retained Earnings was -$4.6 billion in Q3 2025, compared to -$4.4 billion in Q2 2025 and -$4.5 billion in Q1 2025.